Cannabinoids MarketSize, Share & Industry Analysis, 2026-2034By Cannabinoid TypeBy SourceBy Product FormBy Extraction MethodBy ApplicationBy Spectrum ProfileBy Purity GradeBy Route of AdministrationBy Distribution ChannelBy Legal Status
Full title & scope — all 10 axes with their segments
Cannabinoids Market Size, Share & Industry Analysis, By Cannabinoid Type (Cannabidiol, Tetrahydrocannabinol, Cannabigerol, Cannabinol, Cannabichromene, Cannabidiolic Acid, Other Cannabinoids), By Source (Hemp-Derived, Marijuana-Derived, Synthetic, Semi-Synthetic), By Product Form (Isolate, Distillate, Crude Extract, Oils and Tinctures, Capsules and Softgels, Edibles, Topicals, Vapes and Inhalables), By Extraction Method (CO2 Extraction, Solvent Extraction, Solventless Extraction, Chemical Synthesis and Biosynthesis), By Application (Pharmaceuticals, Nutraceuticals and Dietary Supplements, Food and Beverages, Cosmetics and Personal Care, Recreational and Adult Use, Pet and Veterinary Products, Research and Others), By Spectrum Profile (Full-Spectrum, Broad-Spectrum, Isolate), By Purity Grade (Pharmaceutical Grade, Food and Nutraceutical Grade, Cosmetic Grade, Industrial and Research Grade), By Route of Administration (Oral, Topical and Transdermal, Inhalation, Oromucosal Spray, Others), By Distribution Channel (Pharmacies and Drug Stores, Licensed Dispensaries, Online and E-commerce, Specialty and Health Stores, Business-to-Business Bulk Supply), By Legal Status (Prescription, Medical Cannabis Programmes, Adult-Use Regulated, Hemp-Derived Consumer Wellness), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.

- 01By Cannabinoid TypeCannabidiol · Tetrahydrocannabinol · Cannabigerol
- 02By SourceHemp-Derived · Marijuana-Derived · Synthetic
- 03By Product FormIsolate · Distillate · Crude Extract
- 04By Extraction MethodCO2 Extraction · Solvent Extraction · Solventless Extraction
- 05By ApplicationPharmaceuticals · Nutraceuticals and Dietary Supplements · Food and Beverages
- 06By Spectrum ProfileFull-Spectrum · Broad-Spectrum · Isolate
- 07By Purity GradePharmaceutical Grade · Food and Nutraceutical Grade · Cosmetic Grade
- 08By Route of AdministrationOral · Topical and Transdermal · Inhalation
- 09By Distribution ChannelPharmacies and Drug Stores · Licensed Dispensaries · Online and E-commerce
- 10By Legal StatusPrescription · Medical Cannabis Programmes · Adult-Use Regulated
- 11By Region
Market Analysis & Outlook
Cannabinoids are the active compounds of the cannabis and hemp plants, supplied as isolated molecules, distillates and extracts, or produced by chemical synthesis and fermentation. They are sold as pharmaceutical ingredients and approved drugs, as nutraceutical and cosmetic ingredients, and as finished consumer products such as oils, capsules, edibles, topicals and inhalables. Buyers include drug makers, supplement and beverage brands, personal care companies, licensed retailers, pharmacies and patients under medical programmes.
The global cannabinoids market stood at USD 25.44 billion in 2025. A forecast-period rate of 1.5% takes it to USD 28.804 billion by 2034, and the study reports every year in between, passing USD 17.206 billion in 2020, USD 23.322 billion in 2024, USD 25.621 billion in 2026 and USD 26.024 billion in 2030.
70.7% of 2025 revenue sits in Tetrahydrocannabinol (THC), worth USD 17.99 billion and rising to USD 24.375 billion at 84.6% by 2034, the largest cannabinoid type line in both years. Growth is fastest in Tetrahydrocannabinol (THC) at 3.4% and slowest in Other Cannabinoids at -18.2%. Share moves toward Tetrahydrocannabinol (THC) and away from Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Cannabidiolic Acid (CBDA) and Other Cannabinoids, though no line shrinks in revenue terms.
By source, Hemp-Derived accounts for 48% of 2025 revenue at USD 12.211 billion, reaching USD 13.25 billion and 46% by 2034. Synthetic grows faster at 7% against 0.9%, moving from 8% of revenue to 13% by 2034. This axis divides the same revenue as the cannabinoid type split instead of adding to it, so the two are read together and never summed.
Geographically, 86.9% of 2025 revenue sits in North America (USD 22.104 billion rising to USD 22.613 billion) ahead of Europe at 9.2% and USD 2.353 billion. Middle East and Africa is smallest, at 0.5%. Europe, Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.
Coverage extends to five regions, seven cannabinoid type lines and ten segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies, with no independently sourced count behind it, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 25.44 billion in 2025 to USD 28.804 billion in 2034, a compound annual rate of 1.5%, having reached USD 23.322 billion in 2024 from USD 17.206 billion in 2020.
- Tetrahydrocannabinol (THC) is the largest cannabinoid type line at USD 17.99 billion in 2025, a 70.7% share, reaching USD 24.375 billion and 84.6% of revenue by 2034.
- The bull case puts 2034 revenue at USD 35.914 billion and the bear case at USD 23.394 billion, either side of the USD 28.804 billion base case, each with its own stated assumption in the full report.
- North America holds 86.9% of global revenue in 2025 at USD 22.104 billion, the largest of the five regions tracked, and reaches USD 22.613 billion by 2034.
- Within North America, the United States is the worked country example, at USD 19.341 billion in 2025; 87.5% of regional revenue in the base year, and USD 19.616 billion by 2034.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and ten segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By cannabinoid type
Base year 2025Tetrahydrocannabinol (THC) leads with 70.7% of cannabinoid type segment revenue.
Share of cannabinoid type segment revenue, most recent base year. The 1 smallest segments are grouped as Other.
Three things move over 2026-2034, and they are worth separating: the cannabinoid type mix, the regional balance, and the 1.5% compounding underneath both.
All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.
Composition shifts on the cannabinoid type axis. 3.4% against -18.2%: that gap, between Tetrahydrocannabinol (THC) and Other Cannabinoids, is the largest on the cannabinoid type axis. Over the forecast period that moves Tetrahydrocannabinol (THC) from 70.7% of revenue to 84.6%, and Other Cannabinoids from 14.4% to 2.2%. Revenue rises on both sides; USD 17.99 billion to USD 24.375 billion and USD 3.652 billion to USD 0.641 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Growth concentrates in Europe, Asia Pacific, Latin America and Middle East and Africa. Europe moves from 9.2% of revenue in 2025 to 16% in 2034, worth USD 2.353 billion rising to USD 4.619 billion; Asia Pacific moves from 2.2% of revenue in 2025 to 3.2% in 2034, worth USD 0.566 billion rising to USD 0.911 billion; Latin America moves from 1.2% of revenue in 2025 to 1.6% in 2034, worth USD 0.295 billion rising to USD 0.466 billion; Middle East and Africa moves from 0.5% of revenue in 2025 to 0.7% in 2034, worth USD 0.122 billion rising to USD 0.195 billion. Share moves off the others in turn: North America at 86.9% moving to 78.5%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
The series never breaks trajectory. Reading the series: USD 17.206 billion in 2020, USD 23.322 billion in 2024, USD 25.44 billion in 2025, USD 25.621 billion in 2026, USD 26.024 billion in 2030 and USD 28.804 billion in 2034. There is no discontinuity to time, and 1.5% forecast growth against 8.1% historical means the trend continues and does not turn. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the cannabinoid type and regional sections come in.
Market Growth Factors
Growth is concentrated in Tetrahydrocannabinol (THC)
Market Drivers
3- 01Growth is concentrated in Tetrahydrocannabinol (THC)
The fastest line on the cannabinoid type axis is Tetrahydrocannabinol (THC), at 3.4% against the market's 1.5%, taking USD 17.99 billion to USD 24.375 billion and 70.7% of revenue to 84.6%. Nothing else on the axis grows as fast (Other Cannabinoids manages -18.2%) so the blended 1.5% is carried by this one line instead of shared across them. That makes position on the cannabinoid type axis a growth decision, not a product one.
- 02The two largest regions hold most of the base
North America is the largest region at USD 22.104 billion in 2025, 86.9% of global revenue, and reaches USD 22.613 billion by 2034 while holding 78.5%. Europe adds a further 9.2% at USD 2.353 billion, reaching USD 4.619 billion. Between them they hold most of the base and most of the revenue added over the period, so equal-weighting the regions in a plan misstates where the growth is.
- 03Fifteen years of unbroken growth underpin the forecast
The historical period compounded at 8.1%; USD 17.206 billion in 2020, USD 23.322 billion in 2024 and USD 25.44 billion in 2025. The forecast period then runs at 1.5%, ending 2034 at USD 28.804 billion. With the trajectory already demonstrated over fifteen years, what remains uncertain is the mix, not the direction, which is where the segment and regional sections do the work.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | US state-legal market growth outside California and California's 2025 recovery | High | +4.2 | Medium | Medium | Low |
| 2 | German medical cannabis demand after the 2024 reclassification | High | +1.42 | High | High | High |
| 3 | Expansion of national medical programmes outside North America | High | +1.31 | High | High | High |
| 4 | Epidiolex/Epidyolex uptake across indications and territories | Medium-High | +0.76 | High | High | Medium |
| 5 | Canadian legal retail sales growth | Medium-High | +0.64 | Medium | Medium | Low |
| 6 | US floral hemp supply expansion | Low | +0.12 | Low | Low | Low |
| 7 | European and APAC wellness CBD channel growth | Low | +0.06 | Low | Low | Low |
| 8 | Brazilian patient import authorisations | Low | +0.04 | Medium | Medium | Medium |
| Total | +8.54 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | US federal ban on intoxicating hemp-derived products (P.L. 119-37), in force 12 November 2026 | High | −3.11 | Low | Low | Low |
| 2 | Wholesale and retail price compression in mature markets | High | −1.21 | Low | Low | Low |
| 3 | North American hemp-CBD consumer contraction | Medium | −0.37 | Medium | Medium | Low |
| 4 | Continued erosion of the leading North American hemp-CBD filers' revenue | Medium | −0.3 | Medium | Medium | Low |
| 5 | Canadian medical channel shrinking | Low | −0.11 | Low | Low | Low |
| 6 | Regulatory tightening on intoxicating hemp-derived products | Low | −0.06 | Low | Low | Low |
| 7 | Dronabinol utilisation collapse | Low | −0.01 | High | High | High |
| 8 | Sativex erosion | Low | −0 | Low | Low | Low |
| Total | −5.17 | |||||
Drivers contribute 8.54 Billion and restraints remove 5.17 Billion, a net 3.36 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
The 1.5% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the cannabinoid type axis, and where regional growth is concentrated.
Restraining Factors
What holds the forecast back
Market Restraints
2- 01What holds the forecast back
A bear case of USD 23.394 billion in 2034, against USD 28.804 billion in the base case, rests on one stated assumption: every forecast factor at the lower end of its stated range: drivers slower, restraints stronger. Neither case changes the USD 25.44 billion 2025 base.
- 02The largest line is not the fastest
Cannabidiol (CBD) carries 14.2% of 2025 revenue at USD 3.623 billion but compounds at 0.4% against 1.5% for the market, taking its share to 12.7% by 2034 even as revenue rises to USD 3.664 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Upside case: USD 35.914 billion by 2034
Market Opportunities
2- 01Upside case: USD 35.914 billion by 2034
What would beat the forecast: every forecast factor at the upper end of its stated range: drivers faster, restraints milder. That case reaches USD 35.914 billion in 2034 against USD 28.804 billion, and it is worth testing against a reader's own read of the market.
- 02The opening is on the cannabinoid type axis, not the regional one
Share on the cannabinoid type axis moves toward Tetrahydrocannabinol (THC), from 70.7% in 2025 to 84.6% in 2034, on 3.4% growth against the market's 1.5% and revenue rising from USD 17.99 billion to USD 24.375 billion. Taking position there does not require displacing whoever holds Tetrahydrocannabinol (THC), which is the harder and more expensive fight.
Market Challenges
Revenue is concentrated in Tetrahydrocannabinol (THC)
Market Challenges
2- 01Revenue is concentrated in Tetrahydrocannabinol (THC)
USD 17.99 billion of 2025 revenue sits in Tetrahydrocannabinol (THC), 70.7% of the total, and it is still 84.6% at USD 24.375 billion nine years later. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02North America is largely the United States
Of North America's USD 22.104 billion in 2025, USD 19.341 billion (87.5%) comes from the United States alone, rising to USD 19.616 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
10 axesten segmentation axes are reported; by cannabinoid type, by source, product form, extraction method, application, spectrum profile, purity grade, route of administration, distribution channel and legal status. Every one of them divides the same revenue, which makes them views of one market from different commercial angles, not components of it.
Seven cannabinoid type lines are reported. One of them takes share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Cannabinoid Type · 7 segments
By Cannabinoid Type
- Largest Tetrahydrocannabinol (THC) · 70.7%
- Fastest Tetrahydrocannabinol (THC) · 3.4%
- Moves most Tetrahydrocannabinol (THC) · +13.9 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Cannabidiol (CBD) | $3.62B | 14.2% | $3.66B | 12.7%-1.5 | 0.4% |
| Tetrahydrocannabinol (THC) | $17.99B | 70.7% | $24.38B | 84.6%+13.9 | 3.4% |
| Cannabigerol (CBG) | $0.07B | 0.3% | $0.05B | 0.2%-0.1 | -3.6% |
| Cannabinol (CBN) | $0.08B | 0.3% | $0.06B | 0.2%-0.1 | -3.4% |
| Cannabichromene (CBC) | $0.01B | 0% | $0.01B | 0% | -3.5% |
| Cannabidiolic Acid (CBDA) | $0.02B | 0.1% | $0.01B | 0%-0.1 | -3.5% |
| Other Cannabinoids | $3.65B | 14.4% | $0.64B | 2.2%-12.2 | -18.2% |
2025 to 2034 revenue and share by line: Tetrahydrocannabinol (THC) USD 17.99 billion to USD 24.375 billion (70.7% to 84.6%), Other Cannabinoids USD 3.652 billion to USD 0.641 billion (14.4% to 2.2%), Cannabidiol (CBD) USD 3.623 billion to USD 3.664 billion (14.2% to 12.7%), Cannabinol (CBN) USD 0.083 billion to USD 0.059 billion (0.3% to 0.2%), Cannabigerol (CBG) USD 0.066 billion to USD 0.047 billion (0.3% to 0.2%), Cannabidiolic Acid (CBDA) USD 0.017 billion to USD 0.012 billion (0.1% to 0%), Cannabichromene (CBC) USD 0.008 billion to USD 0.006 billion (0% to 0%). Scale and Growth Sit in the Same Line on the Cannabinoid type Axis: Tetrahydrocannabinol (THC) CBD leads because it is legal in the widest range of jurisdictions, has an approved drug use and suits oils, capsules and topicals sold without a prescription. THC holds a large second position through adult-use and medical programmes. Minor cannabinoids grow fastest from a small base, as CBG and CBN gain formulations for sleep, appetite and inflammation, and as fermentation and conversion make them affordable at commercial scale. The order does not change: Tetrahydrocannabinol (THC) is still largest in 2034, and what moves is how much it holds. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Source · 4 segments
Scale in Hemp-Derived and Growth in Synthetic Define the Source Axis
- Largest Hemp-Derived · 48%
- Fastest Synthetic · 7%
- Moves most Synthetic · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hemp-Derived | $12.21B | 48% | $13.25B | 46%-2 | 0.9% |
| Marijuana-Derived | $8.14B | 32% | $8.06B | 28%-4 | -0.1% |
| Synthetic | $2.04B | 8% | $3.75B | 13%+5 | 7% |
| Semi-Synthetic (Converted) | $3.05B | 12% | $3.75B | 13%+1 | 2.3% |
Hemp-derived material leads because it can be grown at scale under agricultural rules and sold across more markets than marijuana-derived material. Synthetic supply grows fastest, since pharmaceutical buyers want consistent purity, traceable batches and independence from crop variation. Semi-synthetic conversion also gains as processors turn abundant CBD into scarcer minor cannabinoids that fetch higher prices. By 2034 Hemp-Derived is still ahead, making this a shift in weight, not a change of leader.
By Product Form · 8 segments
By Product Form
- Largest Oils and Tinctures · 27%
- Fastest Vapes and Inhalables · 9.5%
- Moves most Vapes and Inhalables · +4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Isolate | $3.56B | 14% | $3.17B | 11%-3 | -1.3% |
| Distillate | $4.58B | 18% | $4.90B | 17%-1 | 0.7% |
| Crude Extract | $2.54B | 10% | $2.02B | 7%-3 | -2.6% |
| Oils and Tinctures | $6.87B | 27% | $6.91B | 24%-3 | 0.1% |
| Capsules and Softgels | $2.54B | 10% | $3.46B | 12%+2 | 3.5% |
| Edibles | $2.80B | 11% | $4.03B | 14%+3 | 4.1% |
| Topicals | $1.53B | 6% | $2.02B | 7%+1 | 3.1% |
| Vapes and Inhalables | $1.02B | 4% | $2.31B | 8%+4 | 9.5% |
2025 to 2034 revenue and share by line: Oils and Tinctures USD 6.869 billion to USD 6.912 billion (27% to 24%), Distillate USD 4.579 billion to USD 4.897 billion (18% to 17%), Isolate USD 3.561 billion to USD 3.17 billion (14% to 11%), Edibles USD 2.798 billion to USD 4.032 billion (11% to 14%), Crude Extract USD 2.544 billion to USD 2.016 billion (10% to 7%), Capsules and Softgels USD 2.544 billion to USD 3.456 billion (10% to 12%), Topicals USD 1.526 billion to USD 2.016 billion (6% to 7%), Vapes and Inhalables USD 1.018 billion to USD 2.305 billion (4% to 8%). Vapes and Inhalables Outpaces the Axis While Oils and Tinctures Holds the Largest Share Oils and tinctures lead because they are the familiar entry format, simple to dose and available across pharmacy, online and specialty retail. Vapes and inhalables grow fastest as adult-use markets mature and consumers move toward faster onset. Edibles and capsules also advance with beverage and supplement launches, while crude extract loses ground as buyers prefer refined, tested inputs. By 2034 Oils and Tinctures is still ahead, making this a shift in weight, not a change of leader.
By Extraction Method · 4 segments
Solvent Extraction Led by Extraction method in 2025, with Solventless Extraction Growing Fastest
- Largest Solvent Extraction · 42%
- Fastest Solventless Extraction · 6.1%
- Moves most Chemical Synthesis and Biosynthesis · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| CO2 Extraction | $9.67B | 38% | $9.79B | 34%-4 | 0.1% |
| Solvent Extraction | $10.69B | 42% | $10.66B | 37%-5 | 0% |
| Solventless Extraction | $1.53B | 6% | $2.59B | 9%+3 | 6.1% |
| Chemical Synthesis and Biosynthesis | $3.56B | 14% | $5.76B | 20%+6 | 5.5% |
Solvent extraction leads because it handles large biomass volumes at low cost per kilogram and is established in hemp processing. CO2 extraction holds a close second for buyers who want solvent-free output. Chemical synthesis and biosynthesis grow fastest, driven by pharmaceutical demand for consistent purity and by fermentation routes that supply minor cannabinoids without relying on plant yield. Solvent Extraction remains the largest line through 2034, so the axis changes in proportion, not in order.
By Application · 7 segments
By Application
- Largest Pharmaceuticals · 30%
- Fastest Pharmaceuticals · 4.1%
- Moves most Pharmaceuticals · +8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceuticals | $7.63B | 30% | $10.95B | 38%+8 | 4.1% |
| Nutraceuticals and Dietary Supplements | $7.12B | 28% | $7.49B | 26%-2 | 0.6% |
| Food and Beverages | $2.29B | 9% | $2.59B | 9% | 1.4% |
| Cosmetics and Personal Care | $2.04B | 8% | $2.02B | 7%-1 | -0.1% |
| Recreational and Adult Use | $4.32B | 17% | $3.74B | 13%-4 | -1.6% |
| Pet and Veterinary Products | $1.02B | 4% | $1.44B | 5%+1 | 3.9% |
| Research and Others | $1.02B | 4% | $0.58B | 2%-2 | -6.1% |
2025 to 2034 revenue and share by line: Pharmaceuticals USD 7.632 billion to USD 10.946 billion (30% to 38%), Nutraceuticals and Dietary Supplements USD 7.124 billion to USD 7.49 billion (28% to 26%), Recreational and Adult Use USD 4.324 billion to USD 3.744 billion (17% to 13%), Food and Beverages USD 2.289 billion to USD 2.591 billion (9% to 9%), Cosmetics and Personal Care USD 2.035 billion to USD 2.016 billion (8% to 7%), Pet and Veterinary Products USD 1.018 billion to USD 1.44 billion (4% to 5%), Research and Others USD 1.018 billion to USD 0.576 billion (4% to 2%). Scale and Growth Sit in the Same Line on the Application Axis: Pharmaceuticals Pharmaceuticals lead because approved medicines and prescription programmes carry high value per kilogram of active ingredient. They also grow fastest as more indications win approval, clinicians gain experience and reimbursement widens. Nutraceuticals follow on wide non-prescription reach. Pet products rise with owner spending on animal wellness, while research demand grows slowly because it depends on grant budgets and trial schedules. Pharmaceuticals remains the largest line through 2034, so the axis changes in proportion, not in order.
By Spectrum Profile · 3 segments
Full-Spectrum Led by Spectrum profile in 2025, with Broad-Spectrum Growing Fastest
- Largest Full-Spectrum · 46%
- Fastest Broad-Spectrum · 2.5%
- Moves most Full-Spectrum · -5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Full-Spectrum | $11.70B | 46% | $11.81B | 41%-5 | 0.1% |
| Broad-Spectrum | $7.63B | 30% | $9.51B | 33%+3 | 2.5% |
| Isolate (Single Molecule) | $6.11B | 24% | $7.49B | 26%+2 | 2.3% |
Full-spectrum leads because consumers and clinicians value the combined effect of the plant's compounds and because it needs less processing. Broad-spectrum grows fastest as brands seek THC-free products that meet drug testing and retail rules while keeping more than a single molecule. Isolate holds a steady role in pharmaceutical, food and beverage uses where purity and tasteless formulation matter. Full-Spectrum remains the largest line through 2034, so the axis changes in proportion, not in order.
By Purity Grade · 4 segments
Scale in Food and Nutraceutical Grade and Growth in Pharmaceutical Grade Define the Purity grade Axis
- Largest Food and Nutraceutical Grade · 46%
- Fastest Pharmaceutical Grade · 5.7%
- Moves most Pharmaceutical Grade · +10 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceutical Grade | $5.60B | 22% | $9.22B | 32%+10 | 5.7% |
| Food and Nutraceutical Grade | $11.70B | 46% | $11.81B | 41%-5 | 0.1% |
| Cosmetic Grade | $3.56B | 14% | $3.46B | 12%-2 | -0.3% |
| Industrial and Research Grade | $4.58B | 18% | $4.32B | 15%-3 | -0.6% |
Food and nutraceutical grade leads because supplements and consumer wellness absorb the largest volumes. Pharmaceutical grade grows fastest as approved drugs and clinical programmes require tightly specified, documented material from audited plants. Cosmetic grade follows personal care demand, and industrial and research grade grows slowest, since it depends on laboratory and development budgets that expand gradually. The order does not change: Food and Nutraceutical Grade is still largest in 2034, and what moves is how much it holds.
By Route of Administration · 5 segments
Scale in Oral and Growth in Oromucosal Spray Define the Route of administration Axis
- Largest Oral · 44%
- Fastest Oromucosal Spray · 3.9%
- Moves most Oral · -2 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oral | $11.19B | 44% | $12.10B | 42%-2 | 0.9% |
| Topical and Transdermal | $5.09B | 20% | $5.76B | 20% | 1.4% |
| Inhalation | $4.58B | 18% | $5.18B | 18% | 1.4% |
| Oromucosal Spray | $2.04B | 8% | $2.88B | 10%+2 | 3.9% |
| Others | $2.54B | 10% | $2.88B | 10% | 1.4% |
Oral routes lead because capsules, oils, softgels and edibles suit both prescription and wellness use and are easy to dose. Oromucosal sprays grow fastest as approved medicines using that format reach more countries and patients who prefer faster onset without smoking. Topical and inhalation routes keep stable positions tied to cosmetic, pain relief and adult-use demand. The order does not change: Oral is still largest in 2034, and what moves is how much it holds.
By Distribution Channel · 5 segments
Online and E-commerce Outpaces the Axis While Licensed Dispensaries Holds the Largest Share
- Largest Licensed Dispensaries · 30%
- Fastest Online and E-commerce · 3.7%
- Moves most Licensed Dispensaries · -6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmacies and Drug Stores | $7.12B | 28% | $8.64B | 30%+2 | 2.2% |
| Licensed Dispensaries | $7.63B | 30% | $6.91B | 24%-6 | -1.1% |
| Online and E-commerce | $5.60B | 22% | $7.78B | 27%+5 | 3.7% |
| Specialty and Health Stores | $3.05B | 12% | $3.17B | 11%-1 | 0.4% |
| Business-to-Business Bulk Supply | $2.04B | 8% | $2.31B | 8% | 1.4% |
Licensed dispensaries lead because adult-use and medical programmes in North America route most sales through them. Online and e-commerce grows fastest as hemp-derived wellness products sell directly to consumers and subscription models spread. Pharmacies gain as prescription cannabinoid medicines and supplements enter mainstream retail, while bulk business-to-business supply tracks ingredient contracts. Leadership changes hands: Pharmacies and Drug Stores is the largest line by 2034, not Licensed Dispensaries.
By Legal Status · 4 segments
Prescription (Approved Drugs) Outpaces the Axis While Hemp-Derived Consumer Wellness Holds the Largest Share
- Largest Hemp-Derived Consumer Wellness · 34%
- Fastest Prescription (Approved Drugs) · 5.3%
- Moves most Prescription (Approved Drugs) · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Prescription (Approved Drugs) | $5.09B | 20% | $8.07B | 28%+8 | 5.3% |
| Medical Cannabis Programmes | $5.60B | 22% | $5.76B | 20%-2 | 0.3% |
| Adult-Use Regulated | $6.11B | 24% | $5.76B | 20%-4 | -0.6% |
| Hemp-Derived Consumer Wellness | $8.65B | 34% | $9.22B | 32%-2 | 0.7% |
Hemp-derived consumer wellness leads because it sells in the most places with the least licensing burden. Prescription approved drugs grow fastest as more indications win approval and payers extend coverage. Medical programmes and adult-use regulated sales expand more slowly, held back by licensing limits, tax burdens and slow state and national legalisation. The order does not change: Hemp-Derived Consumer Wellness is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025
Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered, and the one giving up the most — 8.4 points of share move elsewhere by 2034.
- Rank 1 of 5
- 2025 share 86.9%
- By 2034 78.5%
- Revenue $22.10B → $22.61B
86.9% of the global cannabinoids market sits in North America in 2025, worth USD 22.104 billion with USD 22.613 billion projected for 2034. It is a dominant region on this axis, first by revenue throughout the period.
78.5% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Tetrahydrocannabinol (THC) leads here as it does globally, at 70.7% of 2025 revenue, and Tetrahydrocannabinol (THC) again grows fastest at 3.4%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 87.5% of it, growing 1.0×.
- In region 1 of 2
- Of region 87.5%
- Of global 76%
- Revenue $19.34B → $19.62B
The largest single market in North America is the United States, at USD 19.341 billion in 2025 and USD 19.616 billion in 2034. Because it is 87.5% of the region in the base year, North America's totals move with this one country instead of a spread of them. Set against USD 22.104 billion and USD 22.613 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in the United States follows the cannabinoid type mix reported at global level: Tetrahydrocannabinol (THC) is the largest line at 70.7% of 2025 revenue, moving to 84.6% by 2034, while Tetrahydrocannabinol (THC) grows fastest at 3.4% and takes its share from 70.7% to 84.6%. With 87.5% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own cannabinoid type breakdown in the full report.
Cannabinoids in the United States sit under overlapping federal regimes. The Food and Drug Administration regulates them as drugs when therapeutic claims are made, so a supplier needs an approved new drug application, and a handful of cannabidiol-based medicines have taken that route. Hemp-derived material is separated from marijuana under the Agriculture Improvement Act, while the Controlled Substances Act still governs tetrahydrocannabinol-rich products and brings Drug Enforcement Administration registration for handlers. The agency has not cleared cannabinoids as food ingredients or dietary supplements, so labelling must avoid disease claims, and individual states add testing and licensing rules of their own.
In the United States the field is Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc.. Volume and growth sit in the same line, Tetrahydrocannabinol (THC), at 70.7% of 2025 revenue and 3.4% growth. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 1.1×.
- In region 2 of 2
- Of region 10.4%
- Of global 9.1%
- Revenue $2.30B → $2.58B
9.1% of global revenue is generated in Canada; USD 2.303 billion in 2025, reaching USD 2.576 billion in 2034, and 10.4% of North America.
Europe Market Analysis
The 2nd-largest region covered — it picks up 6.8 points of share by 2034, while revenue still grows 2.0×.
- Rank 2 of 5
- 2025 share 9.2%
- By 2034 16%
- Revenue $2.35B → $4.62B
Europe holds 9.2% of the global cannabinoids market in 2025, worth USD 2.353 billion on the way to USD 4.619 billion by 2034. Among the five regions it ranks second by revenue in both years.
16% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 1.5% global rate, so this region warrants separate treatment and should not be scaled off the total.
Segment composition follows the global pattern: Tetrahydrocannabinol (THC) largest at 70.7% of 2025 revenue, Tetrahydrocannabinol (THC) fastest at 3.4%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.
Germany
The largest market in Europe, growing 2.0×.
- In region 1 of 3
- Of region 30%
- Of global 2.8%
- Revenue $0.71B → $1.42B
Germany is the largest market within Europe, generating USD 0.706 billion in 2025 and projected to reach USD 1.423 billion by 2034. At 30% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Against regional totals of USD 2.353 billion in 2025 and USD 4.619 billion in 2034, it is the country the full report breaks out in detail.
Germany buys along the same lines as the market globally; Tetrahydrocannabinol (THC) first at 70.7% of 2025 revenue and 84.6% in 2034, Tetrahydrocannabinol (THC) fastest at 3.4% on a share moving from 70.7% to 84.6%. Since 30% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by cannabinoid type for Germany is reported separately in the full report.
In Germany, medicinal cannabis is controlled by the Federal Institute for Drugs and Medical Devices, which oversees the cannabis agency handling cultivation and import under the Narcotics Act. Prescription cannabinoid medicines need marketing authorisation, and importers and wholesalers must hold narcotics trading licences and follow good manufacturing and distribution practice. Recent medical cannabis legislation moved the plant-based product out of the narcotics category for prescribing, though pharmacy dispensing and quality rules remain. Cannabidiol in foods is treated as a novel food under European Union rules, so authorisation is needed before such products can be marketed with compliant labelling.
The suppliers tracked in this study (Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc.) compete in Germany across the cannabinoid type lines above. One line leads on both counts here: Tetrahydrocannabinol (THC) holds 70.7% of 2025 revenue and compounds fastest at 3.4%. The commercial size of that position is USD 2.353 billion in 2025, moving to USD 4.619 billion by 2034 across the forecast period.
United Kingdom
2nd-largest in Europe, growing 1.9×.
- In region 2 of 3
- Of region 25%
- Of global 2.3%
- Revenue $0.59B → $1.10B
2.3% of global revenue is generated in the United Kingdom; USD 0.588 billion in 2025, reaching USD 1.101 billion in 2034, and 25% of Europe.
Switzerland
3rd-largest in Europe, growing 1.9×.
- In region 3 of 3
- Of region 15%
- Of global 1.4%
- Revenue $0.35B → $0.66B
Within Europe, Switzerland accounts for 15% of regional revenue and 1.4% of the global total, worth USD 0.354 billion in 2025 and USD 0.66 billion by 2034.
Asia Pacific Market Analysis
The 3rd-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 1.6×.
- Rank 3 of 5
- 2025 share 2.2%
- By 2034 3.2%
- Revenue $0.57B → $0.91B
2.2% of the global cannabinoids market sits in Asia Pacific in 2025, worth USD 0.566 billion on the way to USD 0.911 billion by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
3.2% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 1.5% global rate, so this region warrants separate treatment and should not be scaled off the total.
Within the region the cannabinoid type split tracks the global one; 70.7% of 2025 revenue in Tetrahydrocannabinol (THC), fastest growth of 3.4% in Tetrahydrocannabinol (THC). The full report breaks Asia Pacific out along every axis and by country.
China
The largest market in Asia Pacific, growing 1.7×.
- In region 1 of 3
- Of region 31.9%
- Of global 0.7%
- Revenue $0.18B → $0.30B
31.9% of Asia Pacific's base-year revenue comes from China; USD 0.181 billion, rising to USD 0.302 billion by 2034. Its 31.9% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 0.566 billion in 2025 and USD 0.911 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
China buys along the same lines as the market globally; Tetrahydrocannabinol (THC) first at 70.7% of 2025 revenue and 84.6% in 2034, Tetrahydrocannabinol (THC) fastest at 3.4% on a share moving from 70.7% to 84.6%. Its 31.9% weight in Asia Pacific means those movements carry straight into the regional totals. China carries its own cannabinoid type breakdown in the full report.
China regulates cannabinoids chiefly through the National Medical Products Administration for medicines and the Ministry of Public Security for narcotic control. Industrial hemp cultivation is permitted in designated provinces under licence, with strict limits on tetrahydrocannabinol content in the plant. Cannabidiol extracted from hemp may be produced for export, yet it is barred from domestic food and dietary supplement use, and cosmetic use is tightly limited by the cosmetics ingredient inventory. Suppliers of any pharmaceutical candidate must complete clinical trial filing and drug registration, and factories must comply with national manufacturing quality standards and controlled-substance record keeping.
Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc. are the suppliers covered in China. Tetrahydrocannabinol (THC) is both the largest line, at 70.7% of 2025 revenue, and the fastest-growing at 3.4%. A supplier weighted toward Asia Pacific is competing over a base of USD 0.566 billion in 2025, reaching USD 0.911 billion by 2034 on the trajectory this study models.
Australia
2nd-largest in Asia Pacific, growing 1.6×.
- In region 2 of 3
- Of region 13.9%
- Of global 0.3%
- Revenue $0.08B → $0.12B
Within Asia Pacific, Australia accounts for 13.9% of regional revenue and 0.3% of the global total, worth USD 0.079 billion in 2025 and USD 0.123 billion by 2034.
Japan
3rd-largest in Asia Pacific, growing 1.4×.
- In region 3 of 3
- Of region 12.5%
- Of global 0.3%
- Revenue $0.07B → $0.10B
Japan is sized at USD 0.071 billion in 2025, rising to USD 0.099 billion by 2034; 0.3% of global revenue and 12.5% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.4 points of share by 2034.
- Rank 4 of 5
- 2025 share 1.2%
- By 2034 1.6%
- Revenue $0.29B → $0.47B
Latin America holds 1.2% of the global cannabinoids market in 2025, worth USD 0.295 billion rising to USD 0.466 billion in 2034. Among the five regions it ranks fourth by revenue in both years.
1.6% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 1.5%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Tetrahydrocannabinol (THC) leads here as it does globally, at 70.7% of 2025 revenue, and Tetrahydrocannabinol (THC) again grows fastest at 3.4%. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 1.6×.
- In region 1 of 3
- Of region 38%
- Of global 0.4%
- Revenue $0.11B → $0.18B
Brazil is the largest market within Latin America, generating USD 0.112 billion in 2025 and projected to reach USD 0.182 billion by 2034. At 38% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 0.295 billion and USD 0.466 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
The cannabinoid type pattern in Brazil is the global one: 70.7% of 2025 revenue in Tetrahydrocannabinol (THC), 84.6% by 2034, against 3.4% growth in Tetrahydrocannabinol (THC) taking it from 70.7% to 84.6%. Its 38% weight in Latin America means those movements carry straight into the regional totals. Revenue by cannabinoid type for Brazil is reported separately in the full report.
Brazil's health surveillance agency, Anvisa, governs cannabinoid products through a dedicated resolution on manufacturing, importing and selling cannabis-based products. Pharmacies may dispense them against a prescription, and suppliers must obtain sanitary authorisation for each product, which is valid for a limited period and renewable. Product classes are defined by their tetrahydrocannabinol content, with the more potent ones restricted to specific patient groups. Manufacturers must follow good manufacturing practice, submit quality and stability documentation, and meet labelling requirements. Cultivation of the plant remains largely prohibited, so raw material usually comes from imports, which need separate import authorisation.
Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc. are the suppliers covered in Brazil. One line leads on both counts here: Tetrahydrocannabinol (THC) holds 70.7% of 2025 revenue and compounds fastest at 3.4%. A supplier weighted toward Latin America is competing over a base of USD 0.295 billion in 2025, reaching USD 0.466 billion by 2034 on the trajectory this study models.
Colombia
2nd-largest in Latin America, growing 1.6×.
- In region 2 of 3
- Of region 27.9%
- Of global 0.3%
- Revenue $0.08B → $0.13B
0.3% of global revenue is generated in Colombia; USD 0.082 billion in 2025, reaching USD 0.128 billion in 2034, and 27.9% of Latin America.
Mexico
3rd-largest in Latin America, growing 1.6×.
- In region 3 of 3
- Of region 19%
- Of global 0.2%
- Revenue $0.06B → $0.09B
Mexico is sized at USD 0.056 billion in 2025, rising to USD 0.091 billion by 2034; 0.2% of global revenue and 19% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.2 points of share by 2034.
- Rank 5 of 5
- 2025 share 0.5%
- By 2034 0.7%
- Revenue $0.12B → $0.20B
0.5% of the global cannabinoids market sits in Middle East and Africa in 2025, worth USD 0.122 billion rising to USD 0.195 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
By 2034 the share has moved up to 0.7%, because it outgrows the market's 1.5%; the revenue added here is disproportionate to where the region started.
Segment composition follows the global pattern: Tetrahydrocannabinol (THC) largest at 70.7% of 2025 revenue, Tetrahydrocannabinol (THC) fastest at 3.4%. Middle East and Africa is reported axis by axis and country by country in the full study.
Israel
The largest market in Middle East and Africa, growing 1.6×.
- In region 1 of 2
- Of region 33.9%
- Of global 0.2%
- Revenue $0.04B → $0.07B
33.9% of Middle East and Africa's base-year revenue comes from Israel; USD 0.041 billion, rising to USD 0.066 billion by 2034. At 33.9% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. The region itself runs USD 0.122 billion to USD 0.195 billion over the same period, and this is the market carrying the country-level detail in the full report.
Israel buys along the same lines as the market globally; Tetrahydrocannabinol (THC) first at 70.7% of 2025 revenue and 84.6% in 2034, Tetrahydrocannabinol (THC) fastest at 3.4% on a share moving from 70.7% to 84.6%. Its 33.9% weight in Middle East and Africa means those movements carry straight into the regional totals. Revenue by cannabinoid type for Israel is reported separately in the full report.
Israel regulates medical cannabis through the Ministry of Health, which operates a dedicated medical cannabis unit and has moved toward treating the product as a pharmaceutical-grade medicine. Growers, manufacturers and distributors need licences, and products must follow good agricultural and good manufacturing practice, with batch testing and standardised labelling. Physicians are authorised to prescribe, and patients receive licences for specified conditions. Export and import require separate permits, issued under the dangerous drugs framework and the national export oversight rules for medical cannabis. Cannabidiol in foods and cosmetics is subject to the Ministry's own guidance, so suppliers should confirm the classification before launch.
Competition in Israel runs between the suppliers this study tracks: Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc.. One line leads on both counts here: Tetrahydrocannabinol (THC) holds 70.7% of 2025 revenue and compounds fastest at 3.4%. The commercial size of that position is USD 0.122 billion in 2025, moving to USD 0.195 billion by 2034 across the forecast period.
South Africa
2nd-largest in Middle East and Africa, growing 1.7×.
- In region 2 of 2
- Of region 25.7%
- Of global 0.1%
- Revenue $0.03B → $0.05B
0.1% of global revenue is generated in South Africa; USD 0.031 billion in 2025, reaching USD 0.052 billion in 2034, and 25.7% of Middle East and Africa.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by cannabinoid type, source, product form, extraction method, application, spectrum profile, purity grade, route of administration, distribution channel, legal status, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Tetrahydrocannabinol (THC) and Growth in Tetrahydrocannabinol (THC) Set the Terms of Competition
The suppliers covered are: Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc..
Where suppliers actually compete is along the cannabinoid type axis. Tetrahydrocannabinol (THC) is 70.7% of 2025 revenue at USD 17.99 billion and still 84.6% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Share moves in Tetrahydrocannabinol (THC), growing 3.4% against -18.2% for Other Cannabinoids. Holding the first and taking the second are separate capabilities, which is why a market of USD 25.44 billion supports as many suppliers as it does.
Suppliers separate on regulatory standing, extraction and purification scale, and channel reach. Drug makers with approved cannabinoid medicines hold pricing power from clinical data, reimbursement access and pharmacy distribution that others cannot match. Large licensed producers compete on cultivation and processing scale, compliance infrastructure across several jurisdictions and shelf position in dispensaries and retail. Ingredient refiners win on consistent purity, certificate of analysis quality and supply reliability for private-label brands. Smaller and regional players compete on brand, niche formats, minor cannabinoids and local licences, and are most exposed to biomass price swings and testing costs.
Geographic reach is the other axis of competition. North America alone accounts for 86.9% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 9.2%.
The full report carries a profile, financials, share and development history for each company named; none of that is in this summary.
List of Key Cannabinoids Market Companies Profiled
30 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Jazz Pharmaceuticals plc(Ireland)
- Canopy Growth Corporation(Canada)
- Tilray Brands, Inc.(Canada)
- Charlotte's Web Holdings, Inc.(United States)
- Aurora Cannabis Inc.(Canada)
- Curaleaf Holdings, Inc.(United States)
- Cresco Labs Inc.(United States)
- Green Thumb Industries Inc.(United States)
- Trulieve Cannabis Corp.(United States)
- Mile High Labs, Inc.(United States)
- Medterra CBD(United States)
- cbdMD, Inc.(United States)
- Isodiol International Inc.(Canada)
- Elixinol Wellness Limited(Australia)
- Folium Biosciences(United States)
- Cannexus Group
- Cannextra
- Red Mesa Science & Refining(United States)
- Big Sky Scientific(United States)
- Avient Biosciences
- Organigram Global Inc.(Canada)
- SNDL Inc.(Canada)
- Bausch Health Companies Inc.(Canada)
- Neuraxpharm Group(Germany)
- Botanix Pharmaceuticals Limited(Australia)
- Zynerba Pharmaceuticals, Inc.(United States)
- Aphria Inc.(Canada)
- CV Sciences, Inc.(United States)
- Endoca(Denmark)
- Cronos Group Inc.(Canada)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Cannabinoid Type, Source, Product Form, Extraction Method, Application, Spectrum Profile, Purity Grade, Route of Administration, Distribution Channel, Legal Status), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 30 key companies, and the research methodology behind every estimate.
Segmentation
10 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Cannabinoids Market projected to reach?
USD 28.804 Billion by 2034, CAGR 1.5%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 86.9% of global revenue through 2034.
05Which segment leads the market?
Tetrahydrocannabinol (THC) is the largest line by cannabinoid type, at 70.7% of revenue in 2025.
06Who are the key companies profiled?
Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca, Cronos Group Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.